FY2024 Earnings Forecast for MOLN Issued By Leerink Partnrs

Molecular Partners AG (NASDAQ:MOLN) – Leerink Partnrs issued their FY2024 EPS estimates for shares of Molecular Partners in a research report issued to clients and investors on Thursday, March 6th. Leerink Partnrs analyst J. Chang anticipates that the company will post earnings per share of ($1.93) for the year. The consensus estimate for Molecular Partners’ current full-year earnings is ($1.93) per share. Leerink Partnrs also issued estimates for Molecular Partners’ Q4 2024 earnings at ($0.45) EPS and FY2025 earnings at ($1.71) EPS.

Molecular Partners (NASDAQ:MOLN) last released its earnings results on Thursday, March 6th. The company reported ($0.34) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.11. Molecular Partners had a negative return on equity of 39.31% and a negative net margin of 1,043.01%.

Molecular Partners Trading Down 4.4 %

Shares of Molecular Partners stock opened at $4.69 on Monday. The firm has a market capitalization of $189.10 million, a PE ratio of -2.18 and a beta of 1.06. Molecular Partners has a 12 month low of $3.32 and a 12 month high of $12.70. The business’s 50-day moving average price is $5.10 and its 200-day moving average price is $5.36.

Hedge Funds Weigh In On Molecular Partners

An institutional investor recently raised its position in Molecular Partners stock. Suvretta Capital Management LLC increased its stake in Molecular Partners AG (NASDAQ:MOLN) by 455.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,221,494 shares of the company’s stock after acquiring an additional 1,821,494 shares during the period. Suvretta Capital Management LLC owned about 5.50% of Molecular Partners worth $10,548,000 as of its most recent SEC filing. 26.55% of the stock is owned by hedge funds and other institutional investors.

Molecular Partners Company Profile

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.